ArticleAngewandte Chemie (International ed. in English)2026
AND-Logic-Gated Aptamer Switch for Precise Targeting and Regulation of RNA G-Quadruplexes.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
RNA G-quadruplexes (rG4s) play critical roles in gene regulation and cancer progression, yet their precise manipulation in tumor cells remains challenging. rG4-targeting L-RNA aptamers are an emerging class of ligands with exceptional affinity for rG4s; however, their lack of cell type-specific delivery hinders their regulatory and therapeutic potential. Herein, we engineer an activatable bispecific aptamer switch, termed the Allosteric RNA G-quadruplex ON-switch (ARGON), which integrates an rG4-targeting L-RNA Apt.4-1c module (masked by a glutathione (GSH)-cleavable lock strand) with a tumor receptor-targeting Sgc8 DNA aptamer to precisely target rG4s and regulate downstream cellular activities within tumor cells. The AND logic-gated ARGON is activated exclusively in tumor cells that exhibit both tumor receptor overexpression and elevated GSH levels. Following cellular uptake, GSH-triggered lock cleavage exposes L-Apt.4-1c's rG4-binding domain, enabling binding oncogenic Bcl2 rG4. Then activated ARGON regulates rG4-associated tumor cellular functions while sparing normal cells. Besides, we apply ARGON to target human telomerase RNA component (hTERC) rG4 to show our method's generality. Collectively, by integrating cell-surface addressing with intracellular environmental sensing, our work reports an "old-chemistry-new-trick" framework for regulating nucleic acid structures, enabling conditional targeting of cellular RNA structures with minimal off-target effects and propelling aptamer-based precision biomedicine forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.